Exec Chat: Illumina CMO Looks From Pandemic Boom To Future Where Genomics Is ‘Foundational’ To Health Care

08 Feb 2022

Illumina’s chief medical officer Phillip Febbo discusses expanding use cases for gene sequencing, the firm’s planned introduction of new long-read sequencing technology Infinity, the status of its Grail acquisition, and additional plans for 2022.

Illumina, Inc.’s chief medical officer Phillip Febbo expects 2022 will be bright for the San Diego, CA-based gene-sequencing giant.

In an interview with Medtech Insight, Febbo pointed to new product launches, budding partnerships, double-digit revenue growth, and rising awareness...